Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
April 17, 2025
-
REGULATORY MHLW to Revise Patent Linkage Scheme in FY2025, Create Expert Committee
April 16, 2025
-
BUSINESS Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
-
BUSINESS AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
-
BUSINESS Servier Poised to Double Japan Workforce over Next 3 Years: CEO, Local Chief
April 14, 2025
-
REGULATORY Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
-
BUSINESS Japan Biotechs to Be Hit Hard by TSE Growth Market Reform, 26 Firms Fail to Reach Proposed Threshold
April 11, 2025
-
REGULATORY Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
-
REGULATORY Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
-
REGULATORY Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
-
ORGANIZATION No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
-
REGULATORY Public-Private Council Will Meet This Summer: Japan PM
April 8, 2025
-
REGULATORY Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme
April 7, 2025
-
BUSINESS Jump in New Grad Hires Seen with Drug Makers in Japan: 2025 Poll
April 4, 2025
-
REGULATORY Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule
April 3, 2025
-
REGULATORY Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
-
ORGANIZATION JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
April 2, 2025
-
COMMENTARY How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
-
REGULATORY Japan Jittery over Mass Layoffs at FDA, though HHS Says Reviewers Won’t Be Affected
March 31, 2025
-
REGULATORY Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
March 28, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…